The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008
Open accessAbstract
The surveillance of seasonal influenza virus susceptibility to neuraminidase (NA) inhibitors was conducted using an NA inhibition assay. The 50% inhibitory concentration values (IC 50 s) of 4,570 viruses collected globally from October 2004 to March 2008 were determined. Based on mean IC 50 s, A(H3N2) viruses (0.44 nM) were more sensitive to oseltamivir than A(H1N1) viruses (0.91 nM). The opposite trend was observed with zanamivir: 1.06 nM for A(H1N1) and 2.54 nM for A(H3N2). Influenza B viruses exhibited the least susceptibility to oseltamivir (3.42 nM) and to zanamivir (3.87 nM). To identify potentially resistant viruses (outliers), a threshold of a mean IC 50 value + 3 standard deviations was defined for type/subtype and drug. Sequence analysis of outliers was performed to identify NA changes that might be associated with reduced susceptibility. Molecular markers of oseltamivir resistance were found in six A(H1N1) viruses (H274Y) and one A(H3N2) virus (E119V) collected between 2004 and 2007. Some outliers contained previously reported mutations (e.g., I222T in the B viruses), while other mutations [e.g., R371K and H274Y in B viruses and H274N in A(H3N2) viruses) were novel. The R371K B virus outlier exhibited high levels of resistance to both inhibitors (>100 nM). A substantial variance at residue D151 was observed among A(H3N2) zanamivir-resistant outliers. The clinical relevance of newly identified NA mutations is unknown. A rise in the incidence of oseltamivir resistance in A(H1N1) viruses carrying the H274Y mutation was detected in the United States and in other countries in the ongoing 2007 to 2008 season. As of March 2008, the frequency of resistance among A(H1N1) viruses in the United States was 8.6% (50/579 isolates). The recent increase in oseltamivir resistance among A(H1N1) viruses isolated from untreated patients raises public health concerns and necessitates close monitoring of resistance to NA inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The annual impact of seasonal influenza in the US: Measuring disease burden and costs
Molinari, N.-A. M., Ortega-Sanchez, I. R., Messonnier, M. L., Thompson, W. W., Wortley, P. M., Weintraub, E., & Bridges, C. B. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.03.046 · Cited by 1,722
Neuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,094
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J. D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa054512 · Cited by 901
Potier, M., Mameli, L., Bélisle, M., Dallaire, L., & Melançon, S. B. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90362-2 · Cited by 815
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 786
Bright, R. A., Medina, M.-J., Xu, X., Perez-Oronoz, G., Wallis, T. R., Davis, X. M., Povinelli, L., Cox, N. J., & Klimov, A. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67338-2 · Cited by 725
Self-citationOral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Isolation of drug-resistant H5N1 virus
Le, Q. M., Kiso, M., Someya, K., Sakai, Y. T., Nguyen, T. H., Nguyen, K. H. L., Pham, N. D., Ngyen, H. H., Yamada, S., Muramoto, Y., et al. (2005) · Nature · doi:10.1038/4371108a · Cited by 693
Bright, R. A. (2006) · JAMA · doi:10.1001/jama.295.8.joc60020 · Cited by 671
Self-citationDeyde, V. M., Xu, X., Bright, R. A., Shaw, M., Smith, C. B., Zhang, Y., Shu, Y., Gubareva, L. V., Cox, N. J., & Klimov, A. I. (2007) · The Journal of Infectious Diseases · doi:10.1086/518936 · Cited by 543
Self-citation
Cited by
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Harper, S. A., Bradley, J. S., Englund, J. A., File, T. M., Gravenstein, S., Hayden, F. G., McGeer, A. J., Neuzil, K. M., Pavia, A. T., Tapper, M. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598513 · Cited by 647
Triple-Reassortant Swine Influenza A (H1) in Humans in the United States, 2005–2009
Shinde, V., Bridges, C. B., Uyeki, T. M., Shu, B., Balish, A., Xu, X., Lindstrom, S., Gubareva, L. V., Deyde, V., Garten, R. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903812 · Cited by 607
Self-citationAntiviral Natural Products and Herbal Medicines
Lin, L.-T., Hsu, W.-C., & Lin, C.-C. (2014) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.124335 · Cited by 529
Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States
Dharan, N. J. (2009) · JAMA · doi:10.1001/jama.2009.294 · Cited by 527
Drug resistance in influenza A virus: the epidemiology and management
Hussain, M., Galvin, H., Haw, T. Y., Nutsford, A., & Husain, M. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s105473 · Cited by 439
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
McKimm‐Breschkin, J. L. (2013) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12047 · Cited by 390
Noshi, T., Kitano, M., Taniguchi, K., Yamamoto, A., Omoto, S., Baba, K., Hashimoto, T., Ishida, K., Kushima, Y., Hattori, K., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.10.008 · Cited by 381
Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season
Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van der Werf, S., Schweiger, B., Opp, M., Paget, J., van de Kassteele, J., Hay, A. J., et al. (2009) · Emerging infectious diseases · doi:10.3201/eid1504.081280 · Cited by 362
Influenza virus resistance to neuraminidase inhibitors
Samson, M., Pizzorno, A., Abed, Y., & Boivin, G. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.03.014 · Cited by 343
Harper, S. A., Bradley, J. S., Englund, J. A., File, T. M., Gravenstein, S., Hayden, F. G., McGeer, A. J., Neuzil, K. M., Pavia, A. T., Tapper, M. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/604670 · Cited by 321
Hurt, A. C., Ernest, J., Deng, Y.-M., Iannello, P., Besselaar, T. G., Birch, C., Buchy, P., Chittaganpitch, M., Chiu, S.-C., Dwyer, D., et al. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.03.003 · Cited by 277
Hurt, A. C., Besselaar, T. G., Daniels, R. S., Ermetal, B., Fry, A., Gubareva, L., Huang, W., Lackenby, A., Lee, R. T. C., Lo, J., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.06.001 · Cited by 270
Self-citationKamio, N., Imai, K., Shimizu, K., Cueno, M. E., Tamura, M., Saito, Y., & Ochiai, K. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1669-1 · Cited by 36
Metadata
- Authors
- Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I., & Gubareva, L. V.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-09
- Volume
- 52
- Issue
- 9
- Pages
- 3284-3292
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2128060816
- Cited by
- 480
- References
- 36
- FWCI
- 42.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.